𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway

✍ Scribed by Tao Wang; Toshiro Niki; Akiteru Goto; Satoshi Ota; Teppei Morikawa; Yu Nakamura; Etsuko Ohara; Shumpei Ishikawa; Hiroyuki Aburatani; Jun Nakajima; Masashi Fukayama


Book ID
108583843
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
218 KB
Volume
98
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Activation of potassium channels by hypo
✍ A. C. Koong; A. J. Giaccia; G. M. Hahn; A. H. Saad πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 745 KB

Active oxygen species are generated in cells during pathophysiologic conditions such as inflammation and postischemic reperfusion. If oxygen radical scavengers are added before reperfusion, then the magnitude of injury is reduced. We investigated whether free radicals generated following exposure to

Expression of a naturally occurring cons
✍ Mikkel W. Pedersen; Vadim Tkach; Nina Pedersen; Vladimir Berezin; Hans S. Poulse πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 576 KB

## Abstract Tumor cell motility is one of the rate‐limiting steps of invasion, which defines progression toward a more malignant phenotype. Elevated expression of epidermal growth factor receptor (EGFR) in many cancers is associated with progression of superficial to invasive forms of the disease.

Importance of mevalonate-derived product
✍ FaΓ―za Bennis; Gilles Favre; Francis Le Gaillard; Georges Soula πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 French βš– 738 KB

## Abstract HMG‐CoA reductase catalyzes the synthesis of mevalonate, a crucial intermediate in the biosynthesis of cholesterol and non‐sterol isoprenoid compounds essential for cell growth. The HMG‐CoA reductase activity of the A549 tumor cell line is higher than that of normal human fibroblasts. T

Cost-effectiveness of epidermal growth f
✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven